Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07104383 · ClinicalTrials.gov registry record · Phase 3
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
A Phase 3 study of Weight Loss, sponsored by Viking Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,100
- Enrollment target
- 20
- Study locations
NCT07104383: Recruiting Phase 3 study of Weight Loss, sponsored by Viking Therapeutics.
NCT07104383 is a Phase 3 study of Weight Loss that is actively recruiting participants, run by Viking Therapeutics. The registered enrollment target is 1,100 participants, below the 1,492-participant average among 116 other Weight Loss trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07104383, a Phase 3 study of Weight Loss, is actively recruiting participants, sponsored by Viking Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,100 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Conditions Studied
Interventions
- DRUG VK2735
Study Locations (20)
California
- Viking Clinical Site #2071 - Chula Vista
- Viking Clinical Site #2070 - Escondido
- Viking Clinical Site #2054 - Huntington Park
- Viking Clinical Site #2014 - Lake Forest
- Viking Clinical Site #2129 - Lemon Grove
- Viking Clinical Site #2051 - Lincoln
- Viking Clinical Site #2050 - Long Beach
- Viking Clinical Site #2055 - Los Angeles
- Viking Clinical Site #2078 - Manteca
- Viking Clinical Site #2053 - Montclair
Arizona
- Viking Clinical Site #2005 - Chandler
- Viking Clinical Site #2017 - Flagstaff
- Viking Clinical Site #2018 - Peoria
- Viking Clinical Site #2135 - Scottsdale
- Viking Clinical Site #2019 - Tucson
Alabama
- Viking Clinical Site #2037 - Birmingham
- Viking Clinical Site #2064 - Birmingham
- Viking Clinical Site #2128 - Huntsville
- Viking Clinical Site #2081 - Mobile
Arkansas
- Viking Clinical Site #2036 - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2025-06-23 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 3 |
What NCT07104383 shows while recruiting
NCT07104383 is an interventional study that assigns participants to a tested intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus, below the 1,492-participant average among 116 other Weight Loss trials with a reported enrollment target (26% lower).
The record links to 1 condition, with Weight Loss appearing as the primary indexed condition, and to 1 intervention - of which VK2735 is the first listed.
NCT07104383 names 20 study sites across 4 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT07104383 about?
NCT07104383 is a clinical study titled "VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)". This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
What is the current status of trial NCT07104383?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2025-06-23. Estimated completion is 2027-08-01.
What conditions does trial NCT07104383 study?
This clinical trial studies the following conditions: Weight Loss.
What interventions are being tested in trial NCT07104383?
The interventions under investigation include: VK2735 (DRUG).
Who is sponsoring clinical trial NCT07104383?
This trial is sponsored by Viking Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07104383 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Weight Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07104383's enrollment target sits among peer trials
1,100 7th of 116 higher than 110 of 116 other Weight Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Weight Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VK2735 for Weight Management Phase 3
ACTIVE NOT RECRUITING · Phase 3
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss
RECRUITING
-
Metabolic Health, Bones and Nuts During Weight Loss in Adults
RECRUITING · NA
-
FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
RECRUITING · NA
-
Exercise Effects on Adipose Tissue Structure and Function
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI